Advances in the Diagnosis and Treatment of Multiple Sclerosis
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".
Deadline for manuscript submissions: closed (20 February 2024) | Viewed by 5194
Special Issue Editor
Interests: cognitive; multiple sclerosis
Special Issue Information
Dear Colleagues,
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by the inflammation, demyelination, and degeneration of oligodendrocytes and their axons, which are mediated by the activation of cells of the immune system.
MS is the leading cause of progressive neurological disability and the first cause of neurological symptoms in young adults. Because of the high prevalence of MS in the young population, some emerging disease-modifying therapies (DMTs) aiming to control symptoms have been developed; these new drugs have sophisticated capacities for modulating immune function.
Currently, the primary aim of treatment in MS is to reach “no evident disease activity” (NEDA), which is a composite of three related measures of disease activity: (i) no relapses; (ii) no disability progression; and (iii) no MRI activity (such as new or enlarging T2 lesions or Gd-enhancing lesions) (3,4).
DMTs are chosen by evaluating a few factors:
- The control of neuro-inflammation to prevent the accumulation of disabilities and prolong wellness;
- Avoiding cognitive deterioration, fatigue, and depression, which are caused by MS and at the same time worsen the disease;
- The high heterogeneity of prognosis among patients;
- Treatment adherence, which is strictly related to patients’ wishes and expectations.
Several elements must be considered about the use of DMTs. Some are objectively standardized factors such as clinical and radiological criteria, and potential treatment efficacy, while others are more related to subjective interpretation such as cognition status, tolerability, and/or poor adherence to treatment, comorbidities that may influence medication management and metabolism, and personal factors that hinder the suspension or continuation of therapy, such as pregnancy. By means of the new drugs with different pharmacokinetic and pharmacodynamic profiles, it is today possible to choose a tailor-made treatment by defining a patient’s precision medicine.
The aim of this Special Issue of JCM entitled "Advances in the Diagnosis and Treatment of Multiple Sclerosis" is to select various author contributions in order to deeply investigate this topic.
Dr. Marta Altieri
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple sclerosis
- autoimmune disease
- disease-modifying therapies (DMTs)
- neuro-inflammation
- cognitive deterioration
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.